Skip Navigation

Diabetes (type 1 and 2) - inhaled insulin

Inhaled insulin for the treatment of type 1 and type 2 diabetes

Guidance type:  Technology appraisal
Date issued:  December 2006

We will consult on our review plans for this guidance in September 2009.

Reference:  TA113

Summary

In January 2008, Pfizer ceased production of its inhaled insulin product Exubera. NICE technology appraisal 113 on inhaled insulin for diabetes (types I and II) has therefore been made obsolete.

Pfizer have been letting doctors know that they should begin moving their patients off Exubera and onto other medicines that control high blood sugar levels. If you are worried about how you should control your blood sugar levels as a result of this announcement, you should contact your doctor as soon as possible to discuss your options for other blood sugar lowering medications.

25 January 2008

Top

Documents

For healthcare professionals

For patients, carers and the public

Background information

Implementing this guidance

Any further information NICE has produced to help the NHS implement this guideline locally is linked to below:

Top

Search NICE guidance


Advanced guidance search

Related information

See NICE guidance in practice

Related guidance

Click the links below to see guidance on similar topics